Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02019667 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
A Phase 2 study of Seizures and Metabolic Disease, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT02019667 is a Phase 2 study of Seizures and Metabolic Disease that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 19 participants, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02019667, a Phase 2 study of Seizures and Metabolic Disease, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
Objective: To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency. Study Population: Twenty-two children and adults with SSADH deficiency. Design: Double-blind, cross-over, phase II clinical trial. Outcome Measures: The primary outcome measures for drug efficacy will be performance on neuropsychological testing and responses to parent questionnaire. The secondary outcome measure will be TMS parameters of cortical excitation and inhibition. The outcome measures for safety will include clinical examination and neuropsychological tests.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SGS-742
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Washington
- Washington State University - Pullman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-03-31 |
| Est. Completion | 2019-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02019667
The ClinicalTrials.gov registry entry for NCT02019667 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (98% lower). The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Seizures appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02019667 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Washington.
Frequently Asked Questions
What is clinical trial NCT02019667 about?
NCT02019667 is a clinical study titled "Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency". Objective: To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency. Study Population: Twenty-two children and adults with SSADH deficiency. Design: Double-blind, cross-over, phase II clinical trial....
What is the current status of trial NCT02019667?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2014-03-31. Estimated completion is 2019-04-03.
What conditions does trial NCT02019667 study?
This clinical trial studies the following conditions: Seizures, Metabolic Disease.
What interventions are being tested in trial NCT02019667?
The interventions under investigation include: Placebo (DRUG), SGS-742 (DRUG).
Who is sponsoring clinical trial NCT02019667?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02019667 being conducted?
This trial has 2 study locations across Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
RECRUITING · Phase 2
-
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
RECRUITING · Phase 2
-
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Hypovitaminosis D in Neurocritical Patients
COMPLETED · Phase 2
-
Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.